Best Benzo for Sleep? Approved Options, Risks & Alternatives

There is no single best benzodiazepine for sleep, and none of them is a good long-term sleep aid. Five benzodiazepines are FDA-approved for insomnia: temazepam (Restoril), triazolam (Halcion), estazolam, flurazepam and quazepam (Doral). The American Academy of Sleep Medicine (AASM) names only two of them, temazepam and triazolam, as options (a weak recommendation), and both are labeled for short-term use, generally 7 to 10 days. Xanax, Klonopin and Ativan are not approved as insomnia treatments; Ativan's label allows a bedtime dose only when anxiety or short-term situational stress is what keeps you awake.

Every benzodiazepine carries an FDA boxed warning about addiction, physical dependence and withdrawal, and older adults face added risks of falls and confusion. For chronic insomnia, the first treatment that both the American College of Physicians and the AASM recommend is not a pill: it is cognitive behavioral therapy for insomnia (CBT-I). Below is what the drug labels and guidelines say, what physicians in a private online forum told a critical care nurse who asked this question, and what to do if a benzodiazepine is already part of your nights.

Key Takeaways

• Of the five benzodiazepines approved for insomnia, the AASM guideline names only temazepam (for falling and staying asleep) and triazolam (for falling asleep), each for short-term use.
• Alprazolam (Xanax), clonazepam (Klonopin) and lorazepam (Ativan) are anxiety, panic or seizure medications. Using Xanax or Klonopin for sleep is off-label, and Ativan's label covers sleep only when anxiety or short-term stress is the cause; all carry the same boxed warnings.
• Benzodiazepines help you fall asleep faster in the short term, but they shift sleep toward lighter stage 2 sleep and away from deep sleep and REM sleep.
• Physical dependence can develop after several days to weeks of steady use, even as prescribed, so never stop a benzodiazepine suddenly without a plan from your prescriber.
• CBT-I is the recommended first treatment for chronic insomnia, and when medication is needed there are options that are not habit-forming.

Which Benzodiazepines Are FDA-Approved for Sleep?

Five benzodiazepines carry an FDA indication for insomnia. They differ mainly in how long they last, which decides whether they help you fall asleep, help you stay asleep, or leave you groggy the next morning. The half-lives below come from each drug's FDA label.

• Temazepam (Restoril). Approved for the "short-term treatment of insomnia (generally 7 to 10 days)." Its half-life averages about 8.8 hours (range 3.5 to 18.4). The AASM suggests it for both falling asleep and staying asleep.
• Triazolam (Halcion). Also labeled for 7 to 10 days. It is very short-acting (half-life 1.5 to 5.5 hours), so it helps with falling asleep but can wear off before morning. The AASM suggests it for trouble falling asleep. Its label notes that memory loss for events after a dose (anterograde amnesia) may occur at a higher rate than with other benzodiazepine sleep medications.
• Estazolam. Labeled for the short-term management of insomnia, with a half-life of 10 to 24 hours.
• Flurazepam. Its main active metabolite has a half-life of 47 to 100 hours and builds up over 7 to 10 days of nightly use, so next-day carryover is a real concern.
• Quazepam (Doral). Also long-acting: about 39 hours for the drug and 73 hours for a key metabolite.

So Which One Is "Best"?

If a clinician decides a benzodiazepine is reasonable for a short stretch, such as a few nights of acute insomnia around a major stressor, the choice mostly comes down to matching the drug's duration to the problem: shorter-acting for trouble falling asleep, intermediate for waking in the night, and steering away from the long-acting ones when next-day alertness matters. The AASM made recommendations only for temazepam and triazolam; estazolam, flurazepam and quazepam got a literature review but no recommendation, because the trial data available for them were not adequate for the guideline's analyses. "Best" here still means "least risky for a short course," not "good for nightly use."

It also helps to know how modest those recommendations are. Every AASM recommendation for a sleep medication is rated weak, partly because most trials were industry-funded, each drug had only a small number of trials, and results varied between them. The guideline is also meant to be used alongside the AASM's other guidelines on evaluating and treating chronic insomnia.

Why Xanax, Klonopin and Ativan Are Not Sleep Medications

Many people who ask this are thinking of a benzodiazepine they already have, often one prescribed for anxiety. None of the common anxiety benzodiazepines is approved as an insomnia treatment:

• Alprazolam (Xanax) is approved for generalized anxiety disorder and panic disorder. Its half-life averages about 11.2 hours but varies widely between people (6.3 to 26.9 hours).
• Clonazepam (Klonopin) is approved for panic disorder and certain seizure disorders. Its half-life is typically 30 to 40 hours, so a bedtime dose is still in your system the next day.
• Lorazepam (Ativan) is approved for anxiety disorders and short-term relief of anxiety symptoms. Its label also gives a single bedtime dose for insomnia caused by anxiety or short-term situational stress, but it is not a general sleep medication. Its half-life is about 12 hours.

Using Xanax or Klonopin for sleep is off-label, and Ativan's label covers sleep only when anxiety or short-term stress is the cause; all carry the same boxed warnings as the benzodiazepines approved for insomnia. In our experience, when someone says a Xanax is the only thing that lets them sleep, that is a clue rather than a solution: often anxiety, panic or a racing mind at bedtime is what keeps them up, and treating that directly, with therapy or a non-habit-forming medication, tends to improve the sleep as well. Our anxiety treatment page explains that approach.

Do Benzos Help You Sleep? What They Do to Deep Sleep and REM

In the short term, yes. A 2022 network meta-analysis in The Lancet, which pooled 154 double-blind trials with more than 44,000 participants, found benzodiazepines more effective than placebo for the acute treatment of insomnia. The same authors concluded that benzodiazepines, like several other licensed sleep drugs, are either poorly tolerated or lack information about long-term effects.

The catch is the kind of sleep they produce. A systematic review of sleep-lab studies found that benzodiazepines increase stage 2 (lighter) non-REM sleep while reducing deep slow-wave sleep and REM sleep. The extra stage 2 sleep, with fewer awakenings, can make a night feel more solid than it is. So the answer to "does Xanax affect REM sleep?" is yes: like other benzodiazepines, it tends to reduce it.

"Xanax works wonderfully in the short run and you may not even notice any change in deep sleep or REM in the short run, but when used chronically, all benzos tend to diminish deep sleep and REM sleep. Plus it is habit forming and it can produce tolerance rather quickly. It may seem ideal, but this is a false savior."

The Risks: What the FDA and Geriatric Experts Warn About

• Addiction, dependence and withdrawal. In 2020 the FDA required an updated boxed warning, its most prominent warning, for every benzodiazepine, covering abuse, misuse, addiction, physical dependence and withdrawal reactions. The FDA notes that physical dependence can occur when benzodiazepines are taken steadily for several days to weeks, even as prescribed, and that stopping abruptly or cutting the dose too quickly can cause withdrawal reactions, including seizures, which can be life-threatening.
• Opioids and alcohol. The FDA first warned in August 2016 about combining benzodiazepines with opioid pain or cough medicines, and benzodiazepine labels now carry a boxed warning that the combination "may result in profound sedation, respiratory depression, coma, and death." The FDA also advises: do not drink alcohol with benzodiazepines.
• Dose and duration. The temazepam label states that the risks of dependence and withdrawal increase with longer treatment and higher daily doses.
• Sleep-driving and other complex behaviors. Labels for benzodiazepine sleep medications such as temazepam describe "sleep-driving," preparing food or making phone calls while not fully awake, usually with no memory of it afterward.
• Falls, confusion and crashes in older adults. The labels note that drowsiness puts patients, particularly older adults, at higher risk of falls. The American Geriatrics Society's 2023 Beers Criteria advise adults 65 and older to avoid benzodiazepines, stating that in general they "increase the risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults."
• Breathing during sleep. Sleep medications can depress breathing. The triazolam medication guide, for example, asks whether you have lung problems, breathing problems or sleep apnea, and untreated sleep apnea should be ruled out before any sleeping pill.

What About Dementia?

This is the risk patients ask about most, and the honest answer is that it is uncertain. A 2023 umbrella review of five meta-analyses (30 studies) found pooled associations between benzodiazepine use and dementia ranging from 1.38 to 1.78, but rated the evidence weak and the quality of the underlying studies low.

A 2024 analysis from the Rotterdam Study followed 5,443 cognitively healthy older adults for an average of about 11 years. Overall, past benzodiazepine use was not linked to dementia (hazard ratio 1.06). The strongest association was with high cumulative doses of anxiety-type benzodiazepines (1.33), while sleep-type benzodiazepines showed no association (0.92). People still taking a benzodiazepine did have smaller hippocampus, amygdala and thalamus volumes on MRI, and faster shrinkage of the hippocampus over time.

As one physician in the discussion asked: "Cognitive decline is also associated directly with poor sleep, so how can one tell if the decline is from the medication itself rather than the poor sleep?" That is exactly the limitation of observational studies. The uncertainty is a reason for caution, not panic, and never a reason to stop a medication abruptly.

What Physicians Recommend Instead

When a critical care nurse working rotating shifts asked a private online forum of physicians what she should take for sleep instead of an occasional benzodiazepine, the replies split sharply on medications but converged on a few points. Here is how their suggestions line up with the evidence.

CBT-I Comes First

The American College of Physicians recommends that all adults with chronic insomnia receive CBT-I as the initial treatment, a strong recommendation, and the AASM's 2021 guideline also strongly recommends multicomponent CBT-I. It works on the habits, timing and racing thoughts that keep insomnia going: a consistent wake time, using the bed only for sleep (stimulus control), a temporary, structured sleep window (sleep restriction), relaxation, and changing unhelpful beliefs about sleep. Sleep hygiene tips on their own are not enough; the AASM specifically suggests against using sleep hygiene as a stand-alone treatment.

The evidence holds up in people with other health problems, too. A 2025 meta-analysis in JAMA Internal Medicine of 67 randomized trials (5,232 participants with conditions such as cancer, chronic pain and stroke) found CBT-I produced a large improvement in insomnia severity, with a mean dropout rate of 13.3%. Access is also widening: in a 2025 nationwide randomized trial of 336 US adults, a fully automated, FDA-regulated digital CBT-I program (SleepioRx) improved insomnia severity more than online sleep hygiene education, and the benefit was still present at 24 weeks.

TelepsychHealth offers CBT-I by secure video in Illinois, Texas and Florida. Our online insomnia treatment page explains how it works.

Other Prescription Options

When medication is needed alongside CBT-I, physicians in the discussion leaned toward options with less dependence risk than benzodiazepines. Each has trade-offs:

• Low-dose doxepin (Silenor). FDA-approved at 3 mg and 6 mg for trouble staying asleep, and not a controlled substance. The AASM suggests it for sleep maintenance, and the Lancet analysis found it well tolerated, although data on its effectiveness were limited. One physician described it as a "sleep maintenance med" that "usually does not make one sleepy enough to fall asleep." Its label says it is ordinarily not recommended for people with severe sleep apnea.
• Ramelteon. Approved for trouble falling asleep. It is not a controlled substance, and its label reports no physical dependence. The AASM suggests it for sleep onset, though the Lancet analysis found no overall material benefit.
• Trazodone. The alternative physicians in the discussion mentioned most often. "I have a ton of patients who benefit but definitely not all," one psychiatrist said. It is FDA-approved for depression, is not a controlled substance, and is used off-label for sleep. The evidence is mixed: a 2024 meta-analysis of 44 trials (3,935 participants) found it lengthened total sleep time and reduced nighttime awakenings but did not change how long people felt they slept, and more people stopped it because of side effects. The AASM suggests against using it for insomnia. Its label warns that it can add to the effects of alcohol and other sedating medicines and can impair judgment, thinking and motor skills.
• Orexin receptor antagonists: suvorexant (Belsomra), lemborexant (Dayvigo) and daridorexant (Quviviq). FDA-approved for insomnia. A 2025 network meta-analysis of eight trials (5,198 adults) found all three better than placebo and concluded that, because "there is no evidence that DORAs are associated with physiological tolerance, withdrawal symptoms, or rebound insomnia when abruptly discontinued," they "appear to be a favorable choice." They are still Schedule IV controlled substances, can cause sleepiness, and cost more. As one physician put it: "The only downside, and a major downside, is the cost."
• Z-drugs: zolpidem (Ambien), eszopiclone and zaleplon. Not benzodiazepines, though they act on the same receptor. The AASM lists them as options, but they carry a boxed warning about complex sleep behaviors such as sleepwalking and sleep-driving, and the Beers Criteria advise older adults to avoid them. They are Schedule IV controlled substances, and the zolpidem label warns that it can cause physical and psychological dependence, with withdrawal symptoms if it is stopped abruptly.

Which of these, if any, makes sense depends on whether the problem is falling asleep or staying asleep, your other medications, your age and your health. That is a decision to make with a clinician who knows your history, not from a list.

Natural and Over-the-Counter Options

• Melatonin. Popular with physicians in the discussion ("This is how I survived residency," one said), but the AASM suggests against melatonin for chronic insomnia, and the Lancet analysis found no overall material benefit. Product quality is a real problem: a 2023 analysis in JAMA of 25 US melatonin gummies found 22 were inaccurately labeled, with actual melatonin ranging from 74% to 347% of the amount on the label. If anxiety and sleep overlap for you, our post on whether melatonin can help with anxiety goes deeper.
• Sleep-aid antihistamines (diphenhydramine, doxylamine). The AASM suggests against diphenhydramine for insomnia, and the Beers Criteria list first-generation antihistamines as medications older adults should avoid, noting that tolerance develops when they are used as sleep aids.
• Magnesium, L-theanine, valerian and kava. Physicians in the discussion had personal favorites, but magnesium and L-theanine are not among the treatments the AASM guideline recommends, the AASM suggests against valerian, and the National Center for Complementary and Integrative Health notes that kava products have been linked to rare cases of liver injury, some serious or even fatal.

When Shift Work Is the Real Problem

For the nurse who started the discussion, and for many shift workers, the core problem may not be insomnia that needs a pill but a schedule that keeps the body's clock off balance. One psychiatrist explained it this way:

"Rotating schedules is a mood/limbic system destabilizer. Your body's circadian clock is essentially jet lagged often and constantly trying to find balance that it cannot. An occasional Xanax is not a huge issue, essentially you are temporarily inhibiting the system's attempt to restabilize which gives you that rest, but it is not a good long-term solution. Ultimately, this is most likely an external environmental problem, the insomnia is secondary."

Another physician described the real dilemma: as a prescriber, they worried about benzodiazepines and dementia, but in the moment they worried more about an exhaustion-related accident that could hurt them or someone else. They eventually left shift work. Severe sleep deprivation is a safety risk too, which is why shift work deserves its own plan rather than a nightly sedative.

Practical strategies that came up in the discussion:

• Consider dedicated night shifts rather than rotating schedules, if you have the choice.
• Use bright light exposure strategically to help shift your body clock.
• Keep a consistent sleep environment with blackout curtains and white noise.
• Time caffeine carefully, avoiding it in the latter part of a shift.
• Work with a clinician experienced in shift work disorder.

If You Already Take a Benzodiazepine for Sleep

• Do not stop suddenly. Stopping abruptly or cutting the dose too quickly can cause withdrawal reactions, including seizures. Ask your prescriber whether a gradual reduction makes sense for you.
• Expect a plan built around you. A 2025 joint guideline led by the American Society of Addiction Medicine with nine other organizations says clinicians should not stop benzodiazepines abruptly in people likely to be physically dependent, should tailor the taper to the person and adjust it to how they respond, and should offer psychosocial support. For people who take a benzodiazepine for sleep, CBT-I is a natural partner to a taper.
• Do not mix. Avoid alcohol, opioids and other sedating medicines, including other sleep aids, trazodone and sedating antihistamines, unless the clinician prescribing each one knows about all of them.
• Never take someone else's pills, and keep yours locked up.
• Tell your clinician if you are 65 or older, have sleep apnea or lung disease, or have a history of alcohol or drug use, because the risks are higher.

If someone who has taken a benzodiazepine is very hard to wake or is breathing slowly, especially after mixing it with alcohol or opioids, call 911. If you are having thoughts of suicide, call or text 988 to reach the 988 Suicide & Crisis Lifeline.

A Practical Decision Framework

1. Look for what is driving the insomnia. Rule out sleep apnea, restless legs, side effects of other medications, alcohol or other substances, and depression or anxiety. Our posts on how depression affects sleep and substance use and sleep explain two of the most common drivers.
2. Start CBT-I, in person, by video or through a digital program, rather than relying on sleep hygiene tips alone.
3. If medication is needed, match it to the problem (falling asleep or staying asleep), prefer options that are not habit-forming, and reassess regularly.
4. If a benzodiazepine is used, it should be one approved for insomnia, at the lowest effective dose, for the shortest time, never with alcohol or opioids, and with a plan for stopping from the start.

How TelepsychHealth Approaches Insomnia

Our clinicians treat insomnia as a symptom to understand, not just a night to get through. For sleep, we rarely prescribe benzodiazepines. We screen for sleep apnea and look for the anxiety, depression, substance use or schedule problems that keep people awake. In Illinois, Texas and Florida, where we offer therapy, we start with CBT-I. When medication helps, we generally use non-controlled options and review them regularly. The choice rests on clinical judgment rather than a fixed algorithm.

TelepsychHealth provides online psychiatric care for adults in Arizona, California, Connecticut, Florida, Georgia, Illinois, Michigan, Minnesota, New York and Texas, who must be physically located in one of those states during each visit. If insomnia has lasted for months, or you rely on a benzodiazepine to get through the night, you can request an appointment or read more about our online insomnia treatment.

Frequently Asked Questions

Which benzodiazepine is best for sleep?

None is a good long-term sleep aid. Of the five benzodiazepines FDA-approved for insomnia, the AASM names temazepam (for falling and staying asleep) and triazolam (for falling asleep) as options for short-term use, generally 7 to 10 days according to their labels. CBT-I is the recommended first treatment for chronic insomnia.

Is Xanax, Klonopin or Ativan better for insomnia?

None of the three is approved as an insomnia treatment (Ativan's label allows a bedtime dose only for insomnia caused by anxiety or short-term stress). Xanax and Ativan have average half-lives of about 11 to 12 hours, while Klonopin's half-life of 30 to 40 hours means more carryover into the next day. All three carry the same boxed warnings about addiction, dependence and withdrawal. If anxiety is what keeps you awake, treating the anxiety directly is usually a better long-term plan than sedating it every night.

What is the best benzo for sleep and anxiety?

There is not one to recommend for nightly use. When anxiety and insomnia occur together, the usual approach is to treat both directly: therapy such as CBT for anxiety and CBT-I for sleep, and, when medication helps, a non-habit-forming anxiety medication rather than a nightly sedative. See our anxiety treatment page.

Does Xanax affect REM sleep?

Yes. As a class, benzodiazepines, alprazolam among them, tend to reduce REM sleep and deep slow-wave sleep while increasing lighter stage 2 sleep, according to a systematic review of sleep-lab studies.

Is trazodone or Xanax better for sleep? Can you take them together?

Neither is FDA-approved for insomnia. Trazodone is not a controlled substance and is widely used off-label for sleep, although the AASM suggests against it for insomnia. Xanax carries boxed warnings about addiction and dependence. Trazodone's label warns that it can add to the effects of other sedating medicines, so take them together only if a prescriber who knows about both has said so.

Why is trazodone not recommended for insomnia?

The AASM's 2017 guideline suggested against trazodone for insomnia (a weak recommendation) based on the trials available. A 2024 meta-analysis of 44 trials found it lengthened total sleep time and reduced nighttime awakenings but did not change how long people felt they slept, and more people stopped it because of side effects. It is still widely prescribed; whether it fits you is a conversation to have with your clinician.

How long can you take a benzodiazepine for sleep?

The labels for temazepam and triazolam call for short-term use, generally 7 to 10 days. The FDA notes that physical dependence can develop after several days to weeks of steady use. If you have taken one nightly for longer than that, do not stop on your own; ask your prescriber about a gradual taper.

Why don't doctors like to prescribe benzodiazepines for sleep?

Benzodiazepines, including lorazepam (Ativan), carry FDA boxed warnings about addiction, dependence, withdrawal and dangerous interactions with opioids. They are Schedule IV controlled substances, the Beers Criteria advise older adults to avoid them because of falls and confusion, and the long-term evidence is thin. CBT-I works without those risks, which is why guidelines put it first.

References

Guidelines and FDA communications

• Sateia MJ, et al. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(2):307-349. PubMed 27998379
• Edinger JD, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(2):255-262. PubMed 33164742
• Qaseem A, et al. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2016;165(2):125-133. PubMed 27136449
• 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. PubMed 37139824
• Brunner E, et al. Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits. J Gen Intern Med. 2025;40(12):2814-2859. PubMed 40526204
• US Food and Drug Administration. FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class. September 23, 2020. FDA

Research

• De Crescenzo F, et al. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet. 2022;400(10347):170-184. PubMed 35843245
• de Mendonça FMR, et al. Benzodiazepines and Sleep Architecture: A Systematic Review. CNS Neurol Disord Drug Targets. 2023;22(2):172-179. PubMed 34145997
• Wu CC, et al. Benzodiazepine Use and the Risk of Dementia in the Elderly Population: An Umbrella Review of Meta-Analyses. J Pers Med. 2023;13(10):1485. PubMed 37888096
• Hofe IV, et al. Benzodiazepine use in relation to long-term dementia risk and imaging markers of neurodegeneration: a population-based study. BMC Med. 2024;22(1):266. PubMed 38951846
• Kokkali M, et al. Effects of Trazodone on Sleep: A Systematic Review and Meta-analysis. CNS Drugs. 2024;38(10):753-769. PubMed 39123094
• Kishi T, et al. Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis. Transl Psychiatry. 2025;15(1):211. PubMed 40555730
• Scott AJ, et al. Cognitive Behavioral Therapy for Insomnia in People With Chronic Disease: A Systematic Review and Meta-Analysis. JAMA Intern Med. 2025;185(11):1350-1361. PubMed 40982264
• Prather AA, et al. The Effectiveness of Digital Cognitive Behavioral Therapy to Treat Insomnia Disorder in US Adults: Nationwide Decentralized Randomized Controlled Trial. JMIR Ment Health. 2025;12:e84323. PubMed 41343796
• Cohen PA, et al. Quantity of Melatonin and CBD in Melatonin Gummies Sold in the US. JAMA. 2023;329(16):1401-1402. PubMed 37097362
• National Center for Complementary and Integrative Health. Kava. NCCIH

FDA prescribing information (DailyMed)

• Restoril (temazepam), triazolam, estazolam, flurazepam, quazepam
• Xanax (alprazolam), Klonopin (clonazepam), Ativan (lorazepam)
• Silenor (doxepin), ramelteon, Belsomra (suvorexant), Ambien (zolpidem), trazodone

Medical Disclaimer

This article is for informational purposes only and does not constitute medical advice. It draws on FDA drug labeling, clinical practice guidelines, peer-reviewed research, and professional opinions shared in a physician discussion forum. Always talk with a qualified healthcare provider before starting, stopping or changing any medication or treatment for sleep, and never stop a benzodiazepine suddenly on your own. In an emergency, call 911; if you are in crisis or having thoughts of suicide, call or text 988.

About This Guide

This patient education guide was developed by synthesizing insights from medical professionals across multiple specialties, including psychiatry, family medicine, anesthesiology and emergency medicine, together with FDA labeling, clinical practice guidelines and peer-reviewed research. Our goal is to provide evidence-based information to help patients make informed decisions about their sleep health in partnership with their healthcare providers. Updated October 2026 to add FDA label details and current guidelines, and to correct several citations.